2.1 Raw Hemodynamic Data

2.2 Fundamental Hemodynamic Equations: The Bedrock of Internal Medicine

Before interpreting any catheterization data, every trainee must internalize two equations that govern cardiovascular physiology. These are not abstractions — they are the framework through which every hemodynamic abnormality in this case can be understood.

Equation 1: Cardiac Output = Heart Rate × Stroke Volume

CO = HR × SV

This equation reveals why the cardiac output is low. The heart rate is 96 — already mildly tachycardic, meaning the heart is already compensating by beating faster. Despite this compensation, CO is only 2.97 L/min because the stroke volume is catastrophically low at 31 mL. The heart is beating fast enough; it simply cannot eject enough blood per beat. In a dilated cardiomyopathy, the SV drops because the ventricle can’t contract (systolic failure). In this patient, the ventricle can contract (EF 45%) but the chamber is too stiff and too small to fill adequately — resulting in a tiny SV despite reasonable contractility. This distinction matters because the treatment is fundamentally different: systolic failure responds to inotropes and afterload reduction, while a stiff ventricle responds to nothing easily.

Clinical Pearl: When CO is low, always ask: is it the heart rate or the stroke volume? If HR is already elevated and CO is still low, the problem is SV. Then ask why SV is low: is the ventricle dilated and weak (systolic failure — low EF), or is it stiff and small (diastolic/infiltrative failure — preserved EF with low absolute SV)? This patient’s EF of 45% with SV of 31 mL answers the question.

Equation 2: Mean Arterial Pressure = Cardiac Output × Total Peripheral Resistance

MAP = CO × TPR

Rearranged: TPR = MAP / CO

This equation explains why the patient became hypotensive with diuresis and why she needed levophed:

The body maintains blood pressure through two variables: cardiac output and vascular resistance. When CO is fixed at a critically low level (as in a stiff ventricle with no recruitable SV), the only way to maintain MAP is to increase TPR — either endogenously (sympathetic activation, RAAS) or exogenously (vasopressors). This is exactly what happened: the patient’s own compensatory vasoconstriction was maintaining a marginal MAP. When diuresis dropped preload and SV fell further, CO dropped below the threshold where even maximal vasoconstriction could maintain perfusion pressure. Levophed restored the TPR side of the equation, buying room to diurese.

Clinical Pearl: The MAP = CO × TPR equation explains every hemodynamic intervention in the ICU. Vasopressors increase TPR. Inotropes increase CO (by increasing SV). Fluids increase CO (by increasing preload → SV). Diuretics decrease preload → which in most hearts increases SV (descending Starling curve) but in a stiff heart decreases SV (flat curve). Understanding which variable you’re manipulating — and whether the heart can respond — is the difference between helping and harming.

Why These Equations Matter for This Case:

The two equations together explain the entire clinical trajectory:

1. CO = HR × SV: SV is 31 mL because the ventricle is stiff and small (infiltrative physiology). HR of 96 is compensatory but insufficient. CO = 2.97 L/min → CI 1.75 → near-cardiogenic shock.
2. MAP = CO × TPR: With CO fixed at ~3 L/min, MAP depends entirely on TPR. Diuresis drops preload → SV drops → CO drops → MAP drops → AKI. Levophed raises TPR → MAP restored → kidneys perfuse → diuresis possible.
3. The EF of 45% is misleading because EF = SV/EDV. If EDV is small (stiff ventricle doesn’t fill), SV is small, but the ratio can look acceptable. The absolute numbers (SV 31, SVI 18.2, CO 2.97, CI 1.75) tell the truth.

2.3 Derived Parameters and Their Significance

Pulmonary Hypertension Classification:

The key to classifying pulmonary hypertension is determining whether it is pre-capillary (intrinsic pulmonary vascular disease), post-capillary (transmitted from left heart congestion), or combined.

Clinical Pearl: A negative DPG and PVR of ~0 confirms isolated post-capillary pulmonary hypertension (IpcPH, WHO Group 2). The pulmonary vasculature is a passive conduit transmitting elevated left-sided pressures. There is no intrinsic pulmonary vascular disease, meaning the pulmonary hypertension will improve if left heart failure can be treated.

2.4 The RA-to-PCWP Gradient: Why It Matters for Restriction

In classic restrictive cardiomyopathy (including advanced cardiac amyloidosis), both ventricles become equally stiff, producing diastolic pressure equalization — RA mean ≈ RVEDP ≈ PCWP, typically all within 5 mmHg. This patient showed:

• RA mean = 11 mmHg
• RVEDP = ~13 mmHg (RV diastolic)
• PCWP = 30 mmHg
• RA-to-PCWP gradient = 19 mmHg

Clinical Pearl: The 19 mmHg gradient initially argues against restriction but does NOT exclude it. Left-dominant or asymmetric infiltration (where the LV is more heavily involved than the RV) can produce exactly this pattern — PCWP markedly elevated while RA is only modestly elevated. Classic equalization is a late finding that occurs when both ventricles are equally stiff (2).

⚠️ Warning: Do not dismiss infiltrative disease solely because the cath “doesn’t look restrictive.” The absence of equalization may reflect asymmetric disease, volume status at the time of catheterization, or early-stage infiltration.

3.1 Chamber Dimensions and Ventricular Geometry

Clinical Pearl: Concentric hypertrophy (thick walls, normal cavity) in a non-hypertensive patient has a short differential: hypertensive heart disease, aortic stenosis, and infiltrative cardiomyopathy. The aortic valve was wide open (AVA 1.9 cm², mean gradient 6 mmHg), eliminating AS. This pattern — thick walls, normal cavity, severe mass elevation — demands evaluation for amyloid, Fabry disease, or sarcoidosis (1,2,10).

3.2 Ejection Fraction — Why the Numbers Don’t Add Up

The wide spread (31–59%) across methods is itself abnormal. Possible explanations include:

1. Regional variation in function — apical segments contracting while basal/mid segments are impaired, which is the classic amyloid pattern
2. Abnormal myocardial echotexture — amyloid infiltration alters the acoustic properties of myocardium, making endocardial border detection unreliable
3. Apical sparing — in cardiac amyloid, the apex is relatively preserved while the base is severely impaired, producing high EF in views that weight apical function (A4C) and low EF in views that weight basal function (A2C)

⚠️ Warning — The Diagnostic Trap: An EF of 45% should NOT produce a CI of 1.75 L/min/m² or an SV of 31 mL. The stroke volume index (SVI = SV/BSA = 31/1.70 = 18.2 mL/m²) is roughly half the lower limit of normal (33–47 mL/m²) — a degree of output failure incompatible with adequate organ perfusion. In dilated cardiomyopathy or ischemic disease with EF 45%, cardiac output is typically far better maintained because the ventricle is dilated and fills to a larger end-diastolic volume. This hemodynamic-EF mismatch — where a “mildly reduced” EF produces near-cardiogenic-shock hemodynamics — is the hallmark of an infiltrative, stiff, small-cavity ventricle (1,2,7). The EF “looks preserved” because the small stroke volume is ejected from a small end-diastolic volume. The ratio (EF) looks acceptable, but the absolute output (SV and SVI) is critically low. This is why SV and SVI matter more than EF in infiltrative disease.

3.3 Diastolic Parameters: The Most Important Numbers on the Echo

Understanding e’ (e-prime): The e’ velocity, measured by tissue Doppler imaging at the mitral annulus, is a direct measure of how quickly the myocardium relaxes in early diastole. It is relatively independent of preload (unlike the E/A ratio, which can be “pseudonormalized” by elevated filling pressures). An e’ of 4 cm/s means the myocardium is relaxing at less than half the normal rate — it is functionally a brick (3).

Understanding E/e’: The ratio of transmitral E velocity to e’ correlates with left atrial pressure and, by extension, PCWP. An E/e’ of 37 predicts severely elevated filling pressures, which was confirmed invasively (PCWP 30 mmHg on cath). The echo report labeled this as “impaired relaxation” (Grade I diastolic dysfunction), which significantly understates the severity. An E/e’ of 37 with e’ of 4 represents at minimum Grade II, likely transitional to Grade III diastolic dysfunction (3).

Clinical Pearl: The echocardiographer’s interpretation of “impaired relaxation” was based on the E/A ratio of 1.3 (which can look benign) but ignored the tissue Doppler parameters. This is a common error. The E/A ratio can be “pseudonormalized” when elevated LA pressure pushes the E wave back up despite impaired relaxation. The e’ and E/e’ tell the true story. Always check tissue Doppler before accepting an E/A-based diastolic assessment.

3.4 Valvular and Other Findings

Mild regurgitation across all four valves (aortic, mitral, tricuspid, pulmonic) was noted. In isolation, this is unremarkable. In the context of infiltrative cardiomyopathy, multi-valve mild regurgitation is a recognized finding due to amyloid infiltration of the valve leaflets and annulus (1,2). Left atrial volume was severely dilated (major axis 7.2 cm, area 34 cm²), consistent with chronic elevation of LV filling pressures. No pericardial effusion was present (small effusions are common in amyloid, but absence does not exclude it).

4.1 This Patient’s Results

4.2 The CKD Adjustment

Both kappa and lambda free light chains are renally cleared. In CKD, reduced clearance causes both to accumulate. Because kappa is a monomer (~22.5 kDa) and lambda is a dimer (~45 kDa), kappa is more freely filtered and therefore backs up proportionally more in CKD. The CKD-adjusted normal ratio upper limit is approximately 3.1 (some references use 3.0–3.6 depending on the degree of renal impairment) (4,5).

Why this is NOT CKD retention:

1. The ratio of 5.37 exceeds the CKD-adjusted threshold of 3.1. If CKD were the sole explanation, the ratio should stay within the adjusted range.
2. Lambda is LOW-NORMAL, not elevated. In CKD retention, both chains should be elevated. A lambda of 3.24 mg/L is at the floor of normal. This is the signature of clonal suppression — a monoclonal kappa-producing plasma cell clone is crowding out normal immunoglobulin production.
3. The dFLC (difference between involved and uninvolved FLC) = 17.4 − 3.24 = 14.2 mg/L. This parameter is used for AL amyloidosis staging and response monitoring (11).

⚠️ Warning: The oncology consultant attributed the abnormal FLC ratio to CKD. This reasoning fails on two counts: (a) the ratio exceeds the CKD-adjusted range, and (b) CKD elevates both chains — it does not suppress one. A suppressed uninvolved light chain in the setting of an elevated involved chain is clonal biology, not renal physiology (4,5).

4.3 The Mayo Serum Monoclonal Screen Is Negative — But Urine Studies Are Separate and Pending

The Mayo serum monoclonal screen is a single serum panel that includes SPEP, serum immunofixation, and serum free light chain assay. This screen is complete and negative for a monoclonal protein — no M-spike on SPEP, no monoclonal band on serum immunofixation. However, the serum FLC component of that same screen returned the abnormal kappa/lambda ratio of 5.37 discussed above. The oncologist cannot cherry-pick the negative immunofixation while dismissing the abnormal FLC that came from the same panel.

The UPEP, urine immunofixation, and urine free light chains are separate orders and remain pending at the time of this review. These urine studies may still reveal a monoclonal light chain not detectable in serum. Light chains are small enough to be filtered by the glomerulus, and in AL amyloidosis the amyloidogenic light chain is being deposited in tissues and excreted in urine — it may be more readily detected in urine than serum, particularly when the plasma cell clone is small.

Even if the urine studies also return negative, approximately 10–15% of AL amyloidosis patients have no detectable monoclonal protein on any electrophoresis (serum or urine) and are diagnosed solely on abnormal FLC ratio plus tissue confirmation (1,6). AL amyloid is often caused by a tiny plasma cell clone producing small amounts of amyloidogenic light chain — insufficient for electrophoretic detection but devastating to tissues. The serum FLC assay is the most sensitive component of the screen precisely because it detects what electrophoresis misses.

5.1 The Two Tests and What They Measure

5.2 This Patient’s Values

5.3 How to Interpret the Gap

Step 1: Calculate the non-albumin fraction. Non-albumin protein = PCR − ACR = 7.9 − 4.5 = 3.4 g/g Albumin as % of total = ACR/PCR = 4.5/7.9 = 57%

Step 2: Apply the clinical framework.

This patient’s albumin fraction of 57% falls in the range that raises concern for a significant non-albumin (overflow) component. In a patient with nephrotic-range proteinuria, this pattern has a short differential:

1. Free light chain excretion (AL amyloidosis, LCDD, myeloma cast nephropathy) — the leading consideration given the abnormal FLC ratio
2. Tubular proteinuria from AKI — proximal tubular injury releases low-molecular-weight proteins; contributes in the setting of Cr 2→4.5 but typically produces a non-albumin fraction of 0.5–1.5 g/g, not 3.4 g/g
3. IgA nephropathy or other glomerulonephritis with tubular injury — possible but does not explain the FLC abnormality
4. Combined diabetic nephropathy (glomerular albumin loss) + light chain overflow — the most likely composite explanation

Clinical Pearl: Ordering both ACR and PCR simultaneously is inexpensive and provides diagnostic information that neither test alone can offer. When the PCR substantially exceeds the ACR, non-albumin protein is present — and the most common cause of large-volume non-albumin proteinuria is free light chain excretion. This is the single cheapest screening maneuver for detecting light chain involvement of the kidney.

5.4 Why the Serum Albumin Is Relatively Preserved

Serum albumin was 3.3 g/dL — only mildly reduced despite nephrotic-range albuminuria (ACR 4.5 g/g). This seems paradoxical. In classic nephrotic syndrome from membranous or minimal change disease, serum albumin often drops to 1.5–2.5 g/dL.

The explanation: a significant portion of the total urinary protein loss is not albumin — it is light chains. The true albumin-specific urinary losses (~4.5 g/g), while heavy, are partially compensated by hepatic albumin synthesis. If all 7.9 g/g of protein were albumin, serum albumin would be much lower. The relatively preserved serum albumin is itself a clue that the proteinuria is mixed, not purely glomerular.

5.5 Pending Urine Studies

Urine light chain analysis (urine immunofixation and quantitative urine free light chains) was ordered and pending at the time of this review. If positive for monoclonal kappa light chains, this would confirm that the non-albumin proteinuria is light chain overflow, linking the renal and cardiac presentations into a single systemic disease.

6.1 Mayo 2012 Revised Staging for AL Amyloidosis (11)

The staging system assigns one point each for exceeding three thresholds:

The European modification subdivides Stage III into IIIa (NT-proBNP <8,500 pg/mL) and IIIb (≥8,500). Without NT-proBNP directly measured, exact substaging is uncertain, but the overall clinical picture (CI 1.75, vasopressor-dependent diuresis, BNP >4,500) places this patient firmly in the Stage IIIa category at minimum (11,12).

Prognostic implications: Median survival for Stage IIIa AL amyloidosis with treatment is approximately 6–12 months. Without treatment, 3–4 months (11,12).

9.1 Urine Chemistry (Dipstick)

9.2 Urine Microscopy

9.3 What the Sediment Tells Us — A Systematic Approach

Step 1: Is there a glomerular process (GN)? Look for: RBC casts, dysmorphic RBCs, significant hematuria. Finding: RBC 1–2 per HPF, no RBC casts reported. No evidence of active glomerulonephritis. Despite nephrotic-range proteinuria, the sediment is not nephritic. This is important — it means the proteinuria is likely from a non-inflammatory glomerular process (amyloid deposition, diabetic nephropathy) and/or overflow (light chains), not from an inflammatory GN that would produce an active sediment.

Step 2: Is there interstitial nephritis (AIN)? Look for: WBC casts, eosinophiluria, significant pyuria, leukocyte esterase positive. Finding: Leukocyte esterase negative, WBC <1 on day 1 and 5 on day 2 (mild, nonspecific), no WBC casts. No evidence of allergic interstitial nephritis. This is relevant given that the patient has been receiving multiple medications in the ICU.

Step 3: Is there tubular necrosis (ATN/ATI)? Look for: Muddy brown granular casts, renal tubular epithelial cells, pigmented casts. Finding: Granular casts = 2. This is the key finding. Granular casts form when tubular epithelial cell debris degenerates within the tubular lumen. Their presence confirms tubular injury. In this clinical context, the tubular injury is from ischemic ATI — the low cardiac output (CI 1.75) plus aggressive diuresis dropped renal perfusion pressure below the threshold for tubular viability.

Step 4: Is there a prerenal component? Look for: Hyaline casts, concentrated urine (high specific gravity), bland sediment. Finding: Hyaline casts = 5. Hyaline casts are composed of Tamm-Horsfall protein that precipitates in the tubular lumen during low-flow states. They are the hallmark of prerenal physiology — the kidney is underperfused. The specific gravity of 1.020–1.025 further supports this: the kidney is concentrating urine appropriately, meaning tubular function is at least partially preserved (pure ATN typically produces dilute, isosthenuric urine with SG ~1.010).

Clinical Pearl: The combination of hyaline casts (prerenal/low-flow) plus granular casts (tubular injury) tells a coherent story: this is cardiorenal AKI with superimposed ischemic tubular injury. The kidney was underperfused (CI 1.75, then diuresis dropped perfusion further), and the tubules sustained injury. This is not primary renal disease — it is secondary to the cardiac pathology. Treating the kidney means treating the heart.

9.4 The Trace Glucose — A Subtle Finding

Trace glucosuria in a patient without frank hyperglycemia (A1c 6.9%, likely higher but not in diabetic crisis) is worth noting. The renal threshold for glucose is approximately 180 mg/dL. If serum glucose was below this threshold at the time of urine collection, trace glucose could suggest proximal tubular dysfunction — the proximal tubule is failing to fully reabsorb filtered glucose. Causes include ischemic tubular injury (most likely here) or, notably, light chain deposition in the proximal tubule (Fanconi-like syndrome). This is a soft finding but adds to the pattern.

9.5 What Is NOT on the Dipstick — The Protein Discrepancy

The urine dipstick protein reads >=300 mg/dL (maximal). However, the dipstick protein pad detects primarily albumin — it is insensitive to non-albumin proteins including light chains. The fact that the dipstick is maximally positive confirms heavy albuminuria, but it underestimates total proteinuria in this patient because the 43% non-albumin fraction (light chains) is largely invisible to the dipstick. This is why quantitative ACR and PCR are essential — the dipstick alone would miss the overflow component entirely.

⚠️ Warning: A dipstick protein of “>=300” with a PCR of 7.9 g/g seems discordant — the dipstick should read higher for that degree of proteinuria. The explanation: the dipstick underdetects light chains. Never rely on dipstick protein alone when monoclonal gammopathy or overflow proteinuria is in the differential. Always send quantitative ACR and PCR.

10.1 The Organ Systems Involved

10.2 The Connections That Only the Internist Makes

The cardiologist sees heart failure with preserved EF and orders diuretics. The nephrologist sees AKI and nephrotic proteinuria. The oncologist sees an abnormal light chain ratio and attributes it to CKD. The echocardiographer reports “impaired relaxation” and “moderate LVH.” Each subspecialist, operating within their lane, may arrive at a reasonable but incomplete conclusion.

The internist — the physician trained to see the whole patient — is the one who asks: “What single diagnosis explains an EF of 45% producing a CI of 1.75, nephrotic proteinuria with 43% non-albumin fraction, an FLC ratio of 5.37 with a suppressed lambda, concentric LVH with e’ of 4, BNP >4,500, troponin of 60, diuretic resistance with vasopressor dependence, AKI on CKD, anemia, and metabolic acidosis — all in the same patient?”

That question — the integrative question — is the essence of internal medicine. No single subspecialty owns this patient. The diagnosis (still pending at the time of this review) will come from connecting the dots across organ systems, not from any one lab test or imaging study in isolation.

10.3 Teaching Implications

This case is ideal for medical student and resident teaching because it demands:

1. Hemodynamic reasoning — interpreting right heart cath numbers, calculating derived parameters, understanding Starling physiology
2. Echocardiographic interpretation — going beyond the EF to tissue Doppler, understanding pseudonormalization, recognizing the EF-hemodynamic mismatch
3. Renal pathophysiology — reading the urine sediment, dissecting proteinuria composition, understanding cardiorenal syndrome, interpreting FLC in CKD
4. Hematologic reasoning — understanding why negative immunofixation doesn’t exclude disease, why CKD can’t explain the FLC pattern, what dFLC means
5. Critical care physiology — preload dependence, vasopressor-enabled diuresis, the narrow volume window in stiff ventricles
6. Clinical integration — the skill of asking “what ties all of this together?” rather than treating each abnormality as an isolated problem
7. Goals of care — recognizing when diagnostic confirmation may not change management, and having honest conversations with patients and families

Clinical Pearl: The hallmark of a great internist is not knowing more subspecialty knowledge than the subspecialists. It is the ability to integrate findings across organ systems into a coherent clinical narrative. This case is a masterclass in that skill. Every abnormality — the echo, the cath, the urine, the light chains, the biomarkers, the diuretic response — points in the same direction. The internist who sees the pattern will make the diagnosis. The one who treats each finding in isolation will miss it.

10.1 Tc-99m Pyrophosphate (PYP) Scan

Bone scintigraphy with technetium-labeled tracers enables noninvasive diagnosis of ATTR amyloidosis. The landmark multicenter study by Gillmore et al. (2016) demonstrated that grade 2 or 3 myocardial radiotracer uptake combined with absence of a monoclonal protein had 100% specificity and positive predictive value for ATTR cardiac amyloidosis (13).

In this patient: If PYP is strongly positive (grade 2–3), the diagnosis would be ATTR — but this patient has an abnormal FLC ratio, which means a positive PYP cannot be used for noninvasive ATTR diagnosis (the Gillmore criteria require absence of monoclonal gammopathy). If PYP is negative, it strongly argues against ATTR and supports AL as the amyloid subtype.

10.2 Fat Pad Biopsy

Abdominal fat pad aspiration with Congo red staining has a sensitivity of approximately 70–80% for AL amyloidosis. If positive (apple-green birefringence under polarized light), the diagnosis is confirmed, and amyloid subtyping by mass spectrometry determines AL vs. ATTR. If negative, the diagnosis is NOT excluded, and bone marrow biopsy or organ-specific biopsy (renal or endomyocardial) is required.

10.3 Bone Marrow Biopsy

Identifies the plasma cell clone producing amyloidogenic light chains. Includes Congo red staining, kappa/lambda immunohistochemistry, flow cytometry, and laser-capture mass spectrometry for definitive amyloid typing. Can be performed at bedside in the ICU.

11.1 If AL Amyloidosis Confirmed

The standard of care is daratumumab-CyBorD (ANDROMEDA regimen): daratumumab (anti-CD38 antibody) plus cyclophosphamide, bortezomib, and dexamethasone. The ANDROMEDA trial demonstrated a hematologic complete response rate of 53.3% vs. 18.1% with CyBorD alone, with improved organ-deterioration-free survival (14).

11.2 Practical Barriers in This Patient

However, this patient presents formidable treatment challenges. The dexamethasone component carries hemodynamic and glycemic risk in a vasopressor-dependent patient. Dose-attenuated protocols exist for advanced cardiac involvement but have less robust outcome data. Stage IIIb patients were excluded from ANDROMEDA entirely. Furthermore, treatment requires specialized amyloidosis center expertise, and the patient is unlikely to discharge home in the near term — a skilled nursing facility would bear the logistical and financial burden of ongoing therapy.

11.3 If ATTR Amyloidosis Confirmed

Tafamidis (TTR tetramer stabilizer) is the disease-modifying therapy. It is much better tolerated hemodynamically than chemotherapy but the cardiac staging with biomarkers this elevated still portends a difficult prognosis.